 |
| 서울 송파구 방이동 한미약품 본사 (사진 = 연합뉴스) |
[Alpha Biz=(Chicago) Reporter Paul Lee] Hanmi Pharmaceutical announced on the 27th that it has agreed to terminate the contract for consignment production of Genexine COVID-19 vaccines.
According to the public announcement, the main reason for the termination of the contract is Genexine's decision to stop developing the COVID-19 vaccine.
With the termination of the contract, the amount of termination is 23.4 billion won, excluding performance performance from the existing contract amount.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
